Literature DB >> 3409173

Successful imaging of human cancer with indium-111-labeled phospholipid vesicles.

C A Presant1, R T Proffitt, A F Turner, L E Williams, D Winsor, J L Werner, P Kennedy, C Wiseman, K Gala, R J McKenna.   

Abstract

Twenty-four patients with proven primary and/or metastatic cancer received single intravenous injections of phospholipid vesicles containing 0.5 mCi of Indium-111. Gamma camera scintigraphy 1 to 72 hours later visualized tumors in 22 patients (92%), including carcinomas of breast, lung, colon, prostate, kidney, cervix, thyroid, and soft tissue sarcoma, lymphoma, and melanoma. Tumor sites that were identified included soft tissues, bone, lung, liver, lymph node, and spinal cord. There were only two false-positive images in metastatic sites and four false-negative images in metastatic sites. Overall sensitivity for tumors in 97 individual sites was 85%, whereas specificity was 96%. Unsuspected areas of malignancy were seen in the lumbar subdural space, pleura, liver, thyroid, and lung. Besides tumor accumulations, homogeneous uptake was observed in normal liver and spleen. Radiation doses to these two organs were 2.2 and 2.9 cGy/0.5 mCi In-111, respectively. Whole body radiation dose was 0.3 cGy/0.5 mCi. The use of Indium-111-labeled vesicles permits a wide variety of human tumors in primary and metastatic sites to be imaged without toxicity and with radiation doses comparable to other radionuclide scanning techniques.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409173     DOI: 10.1002/1097-0142(19880901)62:5<905::aid-cncr2820620509>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective.

Authors:  R M Fielding
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

2.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

Authors:  D Papahadjopoulos; T M Allen; A Gabizon; E Mayhew; K Matthay; S K Huang; K D Lee; M C Woodle; D D Lasic; C Redemann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

3.  Clinical Cancer Nanomedicine.

Authors:  Joy Wolfram; Mauro Ferrari
Journal:  Nano Today       Date:  2019-03-06       Impact factor: 20.722

4.  Indium-111-labelled liposomes: dosimetry and tumour detection in patients with cancer.

Authors:  A Kubo; K Nakamura; T Sammiya; M Katayama; T Hashimoto; S Hashimoto; H Kobayashi; T Teramoto
Journal:  Eur J Nucl Med       Date:  1993-02

Review 5.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

6.  Model studies directed toward the boron neutron-capture therapy of cancer: boron delivery to murine tumors with liposomes.

Authors:  K Shelly; D A Feakes; M F Hawthorne; P G Schmidt; T A Krisch; W F Bauer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

7.  Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

Authors:  P Guaglianone; K Chan; E DelaFlor-Weiss; R Hanisch; S Jeffers; D Sharma; F Muggia
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 8.  Nuclear molecular imaging with nanoparticles: radiochemistry, applications and translation.

Authors:  D S Abou; J E Pickett; D L J Thorek
Journal:  Br J Radiol       Date:  2015-07-02       Impact factor: 3.039

9.  [18F]-Fluorinated Carboplatin and [111In]-Liposome for Image-Guided Drug Delivery.

Authors:  Narottam Lamichhane; Gajanan K Dewkar; Gobalakrishnan Sundaresan; Rebecca N Mahon; Jamal Zweit
Journal:  Int J Mol Sci       Date:  2017-05-18       Impact factor: 5.923

10.  Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles.

Authors:  Víctor M Blanco; Zhengtao Chu; Kathleen LaSance; Brian D Gray; Koon Yan Pak; Therese Rider; Kenneth D Greis; Xiaoyang Qi
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.